---
title: "BAYRY.US (BAYRY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BAYRY.US/news.md"
symbol: "BAYRY.US"
name: "BAYRY.US"
parent: "https://longbridge.com/en/quote/BAYRY.US.md"
datetime: "2026-05-19T18:35:08.069Z"
locales:
  - [en](https://longbridge.com/en/quote/BAYRY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BAYRY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BAYRY.US/news.md)
---

# BAYRY.US (BAYRY.US) — Related News

### [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md)
*2026-05-19T09:15:24.000Z*
> Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at p

### [Barclays Remains a Buy on Bayer (0P6S)](https://longbridge.com/en/news/286877802.md)
*2026-05-19T07:55:37.000Z*
> Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rati

### [Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News](https://longbridge.com/en/news/286864557.md)
*2026-05-18T22:30:28.000Z*
> Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transi

### [U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer | BAYRY Stock News](https://longbridge.com/en/news/286772840.md)
*2026-05-18T04:41:00.000Z*
> The U.S. FDA has granted Priority Review status to Bayer's HYRNUO® (sevabertinib) for first-line treatment of HER2-mutat